COVID-19 PRECAUTIONS:    VIEW THE practices Arizona Oncology has implemented to protect our patients and their families.
Blog     Careers     About Us     Bill Pay     Patient Portal     QOPI Re-Certification     

Chondrosarcoma clinical trial featured in the Arizona Republic


Select patients with chondrosarcoma are being enrolled in a random, double-blind Phase 2 clinical trial aiming to investigate a potential treatment for the rare and sometimes fatal cancer.


Arizona Oncology, along with Virginia G. Piper Cancer Center Clinical Trials in Scottsdale, will evaluate the productiveness and safety of IPI-926, an inhibitor of the Hedgehog pathway, vs. placebos in patients who have metastatic or locally advanced, inoperable chondrosarcoma. The inhibitor was discovered by and is seeing development through Infinity Pharmaceuticals Inc.


More than 100 patients are expected to be enrolled into the program. There are no approved chemotherapy treatments available for chondrosarcoma, which effects cartilage.


Those looking for information about the trial's participant-eligibility requirements can contact the cancer care coordinator at 480-323-1339 toll free at 877-273-3713 or by e-mail at

Read more:


AZ Oncology

Subscribe to the latest in cancer news — delivered to your inbox.